1-3 of 3
Michael Burgess
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Free
Denis C. Talbot, Malcolm Ranson, Joanna Davies, Michael Lahn, Sophie Callies, Valérie André, Sunil Kadam, Michael Burgess, Christopher Slapak, Anna L Olsen, Peter J. McHugh, Johann S. de Bono, Julian Matthews, Azeem Saleem, Patricia Price
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 6150–6158.
https://doi.org/10.1158/1078-0432.CCR-10-1932
Published: 16 December 2010
View article titled, Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
Open the PDF for Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

Free
Alan Sandler, Michael Gordon, Dinesh P. de Alwis, Isabelle Pouliquen, Lisa Green, Phil Marder, Ajai Chaudhary, Karen Fife, Linda Battiato, Christopher Sweeney, Christopher Jordan, Michael Burgess, Christopher A. Slapak
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3265–3272.
https://doi.org/10.1158/1078-0432.CCR-03-0644
Published: 24 May 2004
View article titled, A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy
Open the PDF for A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy in another window
Journal Articles

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies

Free
Eric H. Rubin, Dinesh P. de Alwis, Isabelle Pouliquen, Lisa Green, Phil Marder, Yong Lin, Rita Musanti, Stephanie L. Grospe, Sharon L. Smith, Deborah L. Toppmeyer, Judy Much, Michael Kane, Ajai Chaudhary, Christopher Jordan, Michael Burgess, Christopher A. Slapak
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3710–3717.
Published: 01 December 2002
View article titled, A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies
Open the PDF for A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies in another window